Rights and permissions
About this article
Cite this article
Starting IFN-β-1a therapy at the time of the first demyelinating event beneficial in patients at high risk of MS. Inpharma Wkly. 1258, 15 (2000). https://doi.org/10.2165/00128413-200012580-00034
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200012580-00034